Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs.
Claudin
ovarian cancer
preclinical animal model
severe combined immunodeficient
swine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
08
2018
accepted:
03
01
2019
entrez:
7
2
2019
pubmed:
7
2
2019
medline:
7
2
2019
Statut:
epublish
Résumé
Ovarian cancer (OvCa) is the most lethal gynecologic malignancy, with two-thirds of patients having late-stage disease (II-IV) at diagnosis. Improved diagnosis and therapies are needed, yet preclinical animal models for ovarian cancer research have primarily been restricted to rodents, for data on which can fail to translate to the clinic. Thus, there is currently a need for a large animal OvCa model. Therefore, we sought to determine if pigs, being more similar to humans in terms of anatomy and physiology, would be a viable preclinical animal model for OvCa. We injected human OSPC-ARK1 cells, a chemotherapy-resistant primary ovarian serous papillary carcinoma cell line, into the neck muscle and ear tissue of four severe combined immune deficient (SCID) and two non-SCID pigs housed in novel biocontainment facilities to study the ability of human OvCa cells to form tumors in a xenotransplantation model. Tumors developed in ear tissue of three SCID pigs, while two SCID pigs developed tumors in neck tissue; no tumors were detected in non-SCID control pigs. All tumor masses were confirmed microscopically as ovarian carcinomas. The carcinomas in SCID pigs were morphologically similar to the original ovarian carcinoma and had the same immunohistochemical phenotype based on expression of Claudin 3, Claudin 4, Cytokeratin 7, p16, and EMA. Confirmation that OSPC-ARK1 cells form carcinomas in SCID pigs substantiates further development of orthotopic models of OvCa in pigs.
Identifiants
pubmed: 30723704
doi: 10.3389/fonc.2019.00009
pmc: PMC6349777
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : R24 OD019813
Pays : United States
Références
Radiology. 2002 Jul;224(1):177-83
pubmed: 12091680
Cancer Res. 2005 May 15;65(10):4334-42
pubmed: 15899825
Curr Pharm Des. 2006;12(11):1421-7
pubmed: 16611125
BMC Cancer. 2010 Jul 02;10:349
pubmed: 20598131
Radiology. 2012 Apr;263(1):149-59
pubmed: 22332064
Ann Oncol. 2012 Sep;23 Suppl 10:x118-27
pubmed: 22987945
PLoS One. 2012;7(10):e43323
pubmed: 23071491
Biores Open Access. 2012 Apr;1(2):63-8
pubmed: 23514746
Eur J Pharm Sci. 2014 Jun 16;57:280-91
pubmed: 23988844
PLoS One. 2013 Oct 09;8(10):e76478
pubmed: 24130776
Histopathology. 2014 Jun;64(7):1004-13
pubmed: 24329781
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7260-5
pubmed: 24799706
J Immunol. 2014 Aug 1;193(3):1496-503
pubmed: 24973446
J Clin Invest. 2014 Sep;124(9):4052-66
pubmed: 25105366
PLoS One. 2014 Dec 01;9(12):e113833
pubmed: 25437445
J Pharmacol Toxicol Methods. 2015 Jul-Aug;74:80-92
pubmed: 25545337
Transgenic Res. 2015 Jun;24(3):509-17
pubmed: 25716163
Int J Cancer. 2015 Dec 1;137(11):2618-29
pubmed: 26060989
PLoS One. 2015 Jul 01;10(7):e0128864
pubmed: 26132737
J Immunol. 2015 Oct 1;195(7):3171-9
pubmed: 26320255
World J Radiol. 2016 May 28;8(5):513-7
pubmed: 27247717
Vet Immunol Immunopathol. 2016 Jul;175:1-6
pubmed: 27269786
Clin Cancer Res. 2016 Jun 15;22(12):2929-38
pubmed: 27306792
Reprod Biol Endocrinol. 2016 Nov 3;14(1):74
pubmed: 27809915
Mol Cancer Ther. 2017 Feb;16(2):323-333
pubmed: 27956521
Mol Imaging Biol. 2017 Jun;19(3):357-362
pubmed: 28271367
Daru. 2017 May 2;25(1):13
pubmed: 28464952
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lab Anim. 2018 Aug;52(4):402-412
pubmed: 29325489
Front Oncol. 2018 Nov 30;8:559
pubmed: 30560086
Yale J Biol Med. 1970 Aug;43(1):22-30
pubmed: 4319305